Silence Therapeutics plc
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
SLN$19.79+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
12. Cash and cash equivalents and short-term investments
| Year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| $000s | $000s | |
| Cash at bank and in hand | 11,277 | 56,590 |
| U.S. treasury bills | - | 64,740 |
| Total cash and cash equivalents | 11,277 | 121,330 |
| U.S. treasury bills | 73,837 | 26,004 |
| Total short-term investments | 73,837 | 26,004 |
Cash at bank comprises balances held by the Group in current, short-term bank deposits, and U.S. Treasury Bills with an original maturity of three months or less. The carrying amount of these assets approximates to their fair value.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.